It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
α-Synuclein aggregates, a key hallmark of the pathogenesis of Parkinson’s disease, can be amplified by using their seeding activity, and the evaluation of the seeding activity of cerebrospinal fluid (CSF) is reportedly useful for diagnosis. However, conventional shaking-based assays are time-consuming procedures, and the clinical significance of the diversity of seeding activity among patients remains to be clarified. Previously, we reported a high-throughput ultrasonication-induced amyloid fibrillation assay. Here, we adapted this assay to amplify and detect α-synuclein aggregates from CSF, and investigated the correlation between seeding activity and clinical indicators. We confirmed that this assay could detect α-synuclein aggregates prepared in vitro and also aggregates released from cultured cells. The seeding activity of CSF correlated with the levels of α-synuclein oligomers measured by an enzyme-linked immunosorbent assay. Moreover, the seeding activity of CSF from patients with Parkinson’s disease was higher than that of control patients. Notably, the lag time of patients with Parkinson’s disease was significantly correlated with the MIBG heart-to-mediastinum ratio. These findings showed that our ultrasonication-based assay can rapidly amplify misfolded α-synuclein and can evaluate the seeding activity of CSF.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Osaka University, Department of Neurology, Graduate School of Medicine, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
2 Osaka University, Institute for Protein Research, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
3 Osaka University, Department of Precision Science and Technology, Graduate School of Engineering, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
4 Kyoto Prefectural University of Medicine, Department of Neurology, Kamikyo-ku, Japan (GRID:grid.272458.e) (ISNI:0000 0001 0667 4960)
5 Osaka University, Department of Neurotherapeutics, Graduate school of Medicine, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
6 Kyoto Prefectural University of Medicine, Department of Molecular Pathobiology of Brain Diseases, Kamikyo-ku, Japan (GRID:grid.272458.e) (ISNI:0000 0001 0667 4960)
7 Hamad Bin Khalifa University (HBKU), Life Sciences Division, College of Science and Engineering, Education City, Qatar (GRID:grid.452146.0) (ISNI:0000 0004 1789 3191)




